AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36511927
Drug: Self-directed, remotely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed, remotely administered behavioral lifestyle intervention (Diabetes Prevention Program-based videos, handouts, coaching messages) for 12 months
Trial: 36511927
Drug: Self-directed, remotely
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed, remotely administered behavioral lifestyle intervention
Trial: 36512069
Drug: Sivopixant 50
RxNorm normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivopixant 50 mg
Trial: 36512069
Drug: Sivopixant 300
RxNorm normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivopixant 300 mg
Trial: 37988255
Drug: Abrocitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abrocitinib (both doses)
Trial: 36512619
Drug: Evocalcet low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet low dose (1-2 mg)
Trial: 36512619
Drug: Evocalcet medium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet medium dose (3-4 mg)
Trial: 36512619
Drug: Evocalcet high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet high dose (5-8 mg)
Trial: 36512619
Drug: Evocalcet (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evocalcet (all doses)
Trial: 36512671
Drug: ABBV-3373 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABBV-3373 (100 mg IV every other week for 12 weeks)
Trial: 36512671
Drug: adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adalimumab (80 mg every other week for 24 weeks)
Trial: 36512738
Drug: Nivolumab 240
RxNorm normalized name: nivolumab 240 MG in 24 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 240 mg once every 2 weeks plus cabozantinib 40 mg once daily (doublet arm)
Trial: 36512738
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks plus cabozantinib 40 mg once daily with ipilimumab 1 mg/kg once every 6 weeks (triplet arm)
Trial: 36513051
Drug: On-label reduced-dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On-label reduced-dose edoxaban
Trial: 36513186
Drug: ARO-HSD 25
RxNorm normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-HSD 25 mg
Trial: 36513186
Drug: ARO-HSD 100
RxNorm normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-HSD 100 mg
Trial: 36513186
Drug: ARO-HSD 200
RxNorm normalized name: HSD-016
DrugBank: HSD-016 (DB12419)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARO-HSD 200 mg
Trial: 36513449
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (136.6 mg as aglycone equivalents)
Trial: 36513490
Drug: Porcine protein
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine protein supplement (twice a day for 6 weeks)
Trial: 36513490
Drug: Maltodextrin supplement
RxNorm normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltodextrin supplement (twice a day for 6 weeks)
Trial: 36513815
Drug: Pressurized intraperitoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with Cisplatin (7.5 mg/m2)
Trial: 36513991
Drug: Immunotherapy (anti-PD1/PDL1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (anti-PD1/PDL1 or anti-CTLA4 monotherapy or combination therapy)
Trial: 36514019
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg tablets taken three times a day)
Trial: 36514143
Drug: Variable dose
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dose anticoagulation
Trial: 36514248
Drug: Benzodiazepine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine and Z-drugs (BZDRs) use
Trial: 36514248
Drug: BZDRs daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BZDRs daily use with increasing doses
Trial: 36514730
Drug: Integrated palliative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated palliative care visits (monthly for 3 months)
Trial: 36514850
Drug: Risankizumab 75
RxNorm normalized name: risankizumab 75 mg/0.83 mL subcutaneous kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab 75 mg
Trial: 36514850
Drug: Risankizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risankizumab (both doses)
Trial: 36515491
Drug: Continuous intrathecal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intrathecal infusion of bupivacaine combined with low-dose fentanyl
Trial: 36515785
Drug: Physical and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical and functional well-being measured by the Functional Assessment of Cancer Therapy-General
Trial: 36515888
Drug: Probiotic BC30
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic BC30 with a 20-g dose of a blend of rice and pea protein
Trial: 36515888
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20-g dose of a blend of rice and pea protein without BC30)
Trial: 36515980
Drug: OmniGraf monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: OmniGraf monitoring in conjunction with medication-related symptom burden (MRSB) monitoring
Trial: 36516076
Drug: Chlorthalidone at
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone at a daily dose of 12.5 or 25 mg
Trial: 36516076
Drug: Hydrochlorothiazide at
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide at a daily dose of 25 or 50 mg
Trial: 36516082
Drug: Patients receiving
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receiving B-cell-directed therapy
Trial: 36516343
Drug: IV ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketamine (0.5-0.75 mg/kg)
Trial: 36517097
Drug: Breathing exercise
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing exercise (BE) intervention; 4-week self-administered program
Trial: 36517235
Drug: Mirogabalin 10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 10 or 15 mg BID for 12 weeks
Trial: 36517235
Drug: Mirogabalin 5
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 5 mg BID for 1 week, 10 mg BID for 1 week
Trial: 36517469
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose of BNT162b2
Trial: 36517740
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard antibiotic therapy without PCT monitoring)
Trial: 36517767
Drug: Erenumab (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (140 mg)
Trial: 36517865
Drug: AV-GBM-1 vaccine
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AV-GBM-1 vaccine administration
Trial: 36518248
Drug: ctDNA-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA-guided therapy
Trial: 36518253
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor letrozole (2.5mg/day; n=11)
Trial: 36518253
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone (1mg/kg/every 4 weeks; n=11)
Trial: 36518729
Drug: Scheduled, simultaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scheduled, simultaneous doses of acetaminophen, celecoxib, and pregabalin; oxycodone 5 mg as needed for breakthrough pain.
Trial: 36518729
Drug: Ibuprofen and
RxNorm normalized name: Ibuprofen and Famotidine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen and oxycodone 5 mg/acetaminophen 325 mg as needed for pain (Control).
Trial: 36518987
Drug: Serum progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serum progesterone levels ≥7.8 ng/ml
Trial: 36518987
Drug: Serum progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Serum progesterone levels <7.8 ng/ml
Trial: 36519287
Drug: 16-week concurrent
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 16-week concurrent exercise program
Trial: 36519749
Drug: Maintenance nivolumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance nivolumab SOC (480 mg 4 weekly)
Trial: 36519749
Drug: Extended interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended interval (480 mg 8 weekly)
Trial: 36520251
Drug: Phase-Advance Intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase-Advance Intervention (PAI): 1 night of late-night wake therapy (LWT: sleep 9 pm-1 am) followed by 7 days of morning bright white light (BWL)
Trial: 36520251
Drug: Phase-Delay Intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase-Delay Intervention (PDI): 1 night of early-night wake therapy (EWT: sleep 3-7 am) plus 7 days of evening BWL
Trial: 36520325
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine (Boostrix) administered on or after the 27th week of pregnancy
Trial: 36520325
Drug: No Tdap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Tdap vaccine during pregnancy (control group)
Trial: 36520426
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg plus Bevacizumab 15 mg/kg on day 1 of each 21-day cycle until disease progression or unacceptable toxic effects.
Trial: 36520462
Drug: SB11 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB11 (0.5 mg)
Trial: 36520462
Drug: RBZ (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBZ (0.5 mg)
Trial: 36520715
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily for six additional weeks
Trial: 36521131
Drug: Integrative couple
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrative couple treatment for pathological gambling (ICT-PG)
Trial: 36521131
Drug: Individual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual treatment approach
Trial: 36521262
Drug: Inhaled single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled single-dose MK-5475 (120 μg and 360 μg)
Trial: 36521262
Drug: Inhaled single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled single-dose MK-5475
Trial: 36521501
Drug: Pegozafermin 3
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 3 mg once weekly
Trial: 36521501
Drug: Pegozafermin 9
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 9 mg once weekly
Trial: 36521501
Drug: Pegozafermin 18
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 18 mg once weekly
Trial: 36521501
Drug: Pegozafermin 27
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 27 mg once weekly
Trial: 36521501
Drug: Pegozafermin 18
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 18 mg once every 2 weeks
Trial: 36521501
Drug: Pegozafermin 36
RxNorm normalized name: Pegozafermin
DrugBank: Pegozafermin (DB19062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegozafermin 36 mg once every 2 weeks
Trial: 36521580
Drug: Hydrodilatation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrodilatation with 40 mg triamcinolone acetonide (TA)
Trial: 36521580
Drug: Hydrodilatation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrodilatation with 10 mg triamcinolone acetonide (TA)
Trial: 36521694
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (identical appearance, intensity/frequency, and duration)
Trial: 36522265
Drug: Toddler dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toddler dose of V114
Trial: 36522265
Drug: Mixed regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed regimens with at least one infant dose plus toddler dose of V114
Trial: 36522279
Drug: Biodynamic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biodynamic drug response classifier (4-level classifier)
Trial: 36522279
Drug: Standard-of-care cytotoxins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care cytotoxins (gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Trial: 36522365
Drug: Mogamulizumab (anti-CCR4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mogamulizumab (anti-CCR4 monoclonal antibody)
Trial: 36522606
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg dapagliflozin daily
Trial: 36522767
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine plus paracetamol
Trial: 36523415
Drug: Bivalent SARS-CoV-2
RxNorm normalized name: SARS-CoV-2 Sclamp
DrugBank: SARS-CoV-2 Sclamp (DB15849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (5 μg of D614 and 5 μg of B.1.351)
Trial: 36524116
Drug: CD38-directed CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD38-directed CAR-T cell therapy
Trial: 36524557
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of maternal characteristics (age, BMI, history of GDM, family history of diabetes) with HbA1c and random plasma glucose.
Trial: 36524810
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (inert pill)
Trial: 36524810
Drug: No-treatment arm
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-treatment arm
Trial: 36525180
Drug: TEC (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEC (docetaxel 75 mg/m2, epirubicin, and cyclophosphamide)
Trial: 36525180
Drug: TECM (docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TECM (docetaxel, epirubicin, cyclophosphamide with metformin)
Trial: 36525338
Drug: Esketamine plus
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine plus a newly initiated oral antidepressant
Trial: 36525493
Drug: Anti-EGFR antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-EGFR antibody combined with neoadjuvant chemotherapy
Trial: 36525493
Drug: Anti-EGFR antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-EGFR antibody
Trial: 39051653
Drug: Adjuvant hepatic
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Trial: 36525620
Drug: TA (Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA (Treatment A)
Trial: 36525620
Drug: Other ablation
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other ablation treatments
Trial: 36525797
Drug: MEDPass (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDPass (50 ml of ONS four times per day with medication rounds)
Trial: 36525797
Drug: Conventional ONS
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ONS administration (between meals)
Trial: 36525797
Drug: Conventional ONS
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional ONS administration
Trial: 36525851
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT) + Fitbit
Trial: 36525851
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) + Fitbit
Trial: 36525985
Drug: Azithromycin 250
RxNorm normalized name: azithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 250 mg (two capsules on day 1 followed by one capsule daily for 4 days)
Trial: 36526425
Drug: Language therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Language therapy for 6 weeks
Trial: 36526425
Drug: Therapy outcome
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy outcome scores
Trial: 36526481
Drug: Preoperative dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative dexamethasone (1 mg/kg)
Trial: 36526521
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg daily) for 6 weeks prior to nephrectomy
Trial: 36526577
Drug: Positron emission
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron emission tomographic (PET) and computed tomographic (CT) imaging using a novel glycoprotein IIb/IIIa receptor antagonist-based radiotracer
Trial: 36526815
Drug: Atovaquone treatment
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atovaquone treatment (Cohort 1, n=14)
Trial: 36526815
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Cohort 2, n=15)
Trial: 36527025
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg RT234
Trial: 36527025
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg RT234
Trial: 36527143
Drug: Oral bolus
RxNorm normalized name: phenylbutazone 1000 MG Oral Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bolus of 100,000 IU with 10,000 IU/week of vitamin D
Trial: 36527367
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of cross-linked hyaluronic acid (HANOX-M-XL)
Trial: 36527702
Drug: Treatment failure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment failure (TF) in C1
Trial: 36528039
Drug: Oral favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral favipiravir plus standard care (1800 mg twice daily for 1 day; 800 mg twice daily for 9 days)
Trial: 36528039
Drug: Oral favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral favipiravir plus standard care (in patients younger than 60 years)
Trial: 36528039
Drug: Oral favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral favipiravir plus standard care
Trial: 36528053
Drug: Telemedicine and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine and medication delivery service (TMDS) called 'MotoMeds'
Trial: 36528376
Drug: Emraclidine 30
RxNorm normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emraclidine 30 mg once daily
Trial: 36528376
Drug: Emraclidine 20
RxNorm normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emraclidine 20 mg twice daily
Trial: 36528443
Drug: DTaP-IPV-HB-PRP∼T vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-HB-PRP∼T vaccine (Hexyon™, Sanofi) administered at 8, 12, 16 weeks and booster at 13 months (preterm) or 15 months (term)